Pipeline & Technologies

Morphogenesis, Inc. and CohBar, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

CohBar Website

Access Webcast Replay

Pipeline

Advancing Innovative Pipeline of Therapies to Overcome Cancer Immunotherapy Resistance

Programs Indications Preclinical Phase 1 Phase 2 Phase 3
Personalized Cancer Vaccine: Intratumoral (PDNA emm55)
IFx-Hu2.0 1st Line Merkel Cell Pembro +/- IFx-Hu2.0
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Primary Checkpoint Inhibitor Resistant Metastatic Cancer "Basket" Trial
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Personalized Cancer Vaccine: Intravenous Targeted (mRNA emm55)
IFx-Hu3.0
scFv-LNP-mRNA		 Diffuse Large B-Cell Lymphoma (DLBCL)
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Tumor Microenvironment Modulators: MDSC Bi-Functional Inhibitors
Nal - anti TIGIT
Nal - OX40		 Myelodysplasia
Acute Myeloid Leukemia
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Immune Fx (IFx) Personalized Cancer Vaccines

Key Technology Benefits

  • Increases T-cell infiltration in treated and untreated lesions (abscopal effect)
  • Leads to production of IgM and IgG with epitope recognition to hundreds of new tumor-associated antigens
  • Gene signature associated with innate response in the injected lesions (CXCL13, LAG3, CXCL11, CXCL10, ICOS)
  • Gene signature associated with adaptive response in un-injected lesions (IL-12, HLA-DRB5, WNT4, CD3D, Arg I)
Our Technologies

Tumor Microenvironment Modulators

Key Technology Benefits

  • Blocks myeloid derived suppressor cell (MDSC) production of multiple immune suppressing soluble factors
  • Converts tumorigenic (tumor growth and spread) microenvironment to immunogenic (immune cell infiltration and attack)
  • Prevents immune cell exhaustion (T-cell, NK cell, CAR-T)
  • Overcomes resistance to checkpoint inhibitors
  • Increases safety and efficacy of immuno- and cellular-therapy
Tumor Microenvironment Modulators